Competing-risk regression for transformation to AML in patients with MDS
| Characteristic . | HR . | 95% CI . | P value . |
|---|---|---|---|
| Autoimmune disease∗ | 1.04 | 0.90-1.19 | .631 |
| Immunosuppressive treatment† | 0.99 | 0.80-1.21 | .892 |
| Age group, y | |||
| 65-70 | Reference | ||
| 70-75 | 0.86 | 0.65-1.13 | .278 |
| 75-80 | 0.71 | 0.54-0.93 | .013 |
| >80 | 0.55 | 0.42-0.72 | <.001 |
| Female sex‡ | 0.83 | 0.75-0.922 | .001 |
| Race/ethnicity | |||
| Non-Hispanic White | Reference | ||
| Non-Hispanic Black | 0.81 | 0.62-1.06 | .116 |
| Hispanic | 1.03 | 0.65-1.62 | .901 |
| Other§ | 1.02 | 0.83-1.24 | .868 |
| Rural residence‖ | 0.85 | 0.73-1.01 | .06 |
| CCI | |||
| 0-1 | Reference | ||
| 2-4 | 0.92 | 0.82-1.03 | .125 |
| >4 | 0.67 | 0.56-0.81 | <.001 |
| MDS histologic risk | |||
| Low | Reference | ||
| Intermediate | 2.61 | 2.09-3.24 | <.001 |
| High | 9.49 | 7.52-11.98 | <.001 |
| Transfusion dependence¶ | |||
| Red blood cells | 1.71 | 1.51-1.93 | <.001 |
| Platelets | 4.46 | 3.81-5.21 | <.001 |
| HMA (≥4 cycles)# | 2.37 | 2.06-2.73 | <.001 |
| Characteristic . | HR . | 95% CI . | P value . |
|---|---|---|---|
| Autoimmune disease∗ | 1.04 | 0.90-1.19 | .631 |
| Immunosuppressive treatment† | 0.99 | 0.80-1.21 | .892 |
| Age group, y | |||
| 65-70 | Reference | ||
| 70-75 | 0.86 | 0.65-1.13 | .278 |
| 75-80 | 0.71 | 0.54-0.93 | .013 |
| >80 | 0.55 | 0.42-0.72 | <.001 |
| Female sex‡ | 0.83 | 0.75-0.922 | .001 |
| Race/ethnicity | |||
| Non-Hispanic White | Reference | ||
| Non-Hispanic Black | 0.81 | 0.62-1.06 | .116 |
| Hispanic | 1.03 | 0.65-1.62 | .901 |
| Other§ | 1.02 | 0.83-1.24 | .868 |
| Rural residence‖ | 0.85 | 0.73-1.01 | .06 |
| CCI | |||
| 0-1 | Reference | ||
| 2-4 | 0.92 | 0.82-1.03 | .125 |
| >4 | 0.67 | 0.56-0.81 | <.001 |
| MDS histologic risk | |||
| Low | Reference | ||
| Intermediate | 2.61 | 2.09-3.24 | <.001 |
| High | 9.49 | 7.52-11.98 | <.001 |
| Transfusion dependence¶ | |||
| Red blood cells | 1.71 | 1.51-1.93 | <.001 |
| Platelets | 4.46 | 3.81-5.21 | <.001 |
| HMA (≥4 cycles)# | 2.37 | 2.06-2.73 | <.001 |
Reference group comprises those with absence of autoimmune disease.
Reference group comprises those with absent exposure to immunosuppressive treatment before MDS diagnosis.
Reference group comprises those with male sex.
Includes Asian/Native Hawaiian/Pacific Islander and American Indian/Alaska Native.
Reference group comprises those with urban residence.
Reference group comprises those with absence of transfusion dependence.
Reference group comprises those with absence of sustained HMA treatment for at least 4 cycles.